It’s only fair to share… BICTEGRAVIR, NEW PATENT, WO 2018005328, CONCERT PHARMA WO2018005328) DEUTERATED BICTEGRAVIR CONCERT PHARMACEUTICALS, INC. TUNG, Roger, D.; (US) Concert CEO Roger Tung Novel deuterated forms of bictegravir is claimed. Gilead Sciences is developing the integrase inhibitor bictegravir as an oral tablet for the treatment of HIV-1 infection. This invention relates to …